- Home
- Publications
- Publication Search
- Publication Details
Title
The past, present, and future of basal insulins
Authors
Keywords
-
Journal
DIABETES-METABOLISM RESEARCH AND REVIEWS
Volume 32, Issue 6, Pages 478-496
Publisher
Wiley
Online
2015-10-29
DOI
10.1002/dmrr.2763
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 1 Diabetes: A Randomized, Phase 3a, Open-Label Clinical Trial (EDITION 4)
- (2015) Philip D. Home et al. DIABETES CARE
- Low within- and between-day variability in exposure to new insulin glargine 300 U/ml
- (2015) R. H. A. Becker et al. DIABETES OBESITY & METABOLISM
- One-year sustained glycaemic control and less hypoglycaemia with new insulin glargine 300 U/ml compared with 100 U/ml in people with type 2 diabetes using basal plus meal-time insulin: the EDITION 1 12-month randomized trial, including 6-month extension
- (2015) M. C. Riddle et al. DIABETES OBESITY & METABOLISM
- New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3)
- (2015) G. B. Bolli et al. DIABETES OBESITY & METABOLISM
- Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes
- (2014) Silvio E. Inzucchi et al. DIABETES CARE
- Basal Insulin Peglispro Demonstrates Preferential Hepatic Versus Peripheral Action Relative to Insulin Glargine in Healthy Subjects
- (2014) Robert R. Henry et al. DIABETES CARE
- 1. Strategies for Improving Care
- (2014) DIABETES CARE
- New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Basal and Mealtime Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 1)
- (2014) Matthew C. Riddle et al. DIABETES CARE
- New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Oral Agents and Basal Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 2)
- (2014) Hannele Yki-Järvinen et al. DIABETES CARE
- New Insulin Glargine 300 units{middle dot}mL-1 Provides a More Even Activity Profile and Prolonged Glycemic Control at Steady State Compared With Insulin Glargine 100 units{middle dot}mL-1
- (2014) R. H. A. Becker et al. DIABETES CARE
- Single-dose new insulin glargine 300 U/ml provides prolonged, stable glycaemic control in Japanese and European people with type 1 diabetes
- (2014) M. Shiramoto et al. DIABETES OBESITY & METABOLISM
- Investigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/ml
- (2014) A. Steinstraesser et al. DIABETES OBESITY & METABOLISM
- Single-dose pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 in healthy subjects
- (2014) Vikram P. Sinha et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Comparison of glucose variability assessed by a continuous glucose-monitoring system in patients with type 2 diabetes mellitus switched from NPH insulin to insulin glargine: The COBIN2 study
- (2014) Denisa Janickova Zdarska et al. WIENER KLINISCHE WOCHENSCHRIFT
- Insulin Degludec Versus Insulin Glargine in Type 1 and Type 2 Diabetes Mellitus: A Meta-Analysis of Endpoints in Phase 3a Trials
- (2014) Jiten Vora et al. Diabetes Therapy
- Insulin Degludec: A Novel Basal Insulin Analogue
- (2013) Jennifer D Goldman-Levine et al. ANNALS OF PHARMACOTHERAPY
- Novel PEGylated Basal Insulin LY2605541 Has a Preferential Hepatic Effect on Glucose Metabolism
- (2013) M. C. Moore et al. DIABETES
- The Efficacy and Safety of Insulin Degludec Given in Variable Once-Daily Dosing Intervals Compared With Insulin Glargine and Insulin Degludec Dosed at the Same Time Daily: A 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes
- (2013) L. Meneghini et al. DIABETES CARE
- Once-daily initiation of basal insulin as add-on to metformin: a 26-week, randomized, treat-to-target trial comparing insulin detemir with insulin glargine in patients with type 2 diabetes
- (2013) L. Meneghini et al. DIABETES OBESITY & METABOLISM
- PEGylated insulin Lispro, (LY2605541)-a new basal insulin analogue
- (2013) T. M. Caparrotta et al. DIABETES OBESITY & METABOLISM
- Steady-state pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 dosed once-daily in patients with type 2 diabetes mellitus
- (2013) V. P. Sinha et al. DIABETES OBESITY & METABOLISM
- Daily insulin doses and injection frequencies of neutral protamine hagedorn (NPH) insulin, insulin detemir and insulin glargine in type 1 and type 2 diabetes: a multicenter analysis of 51 964 patients from the German/Austrian DPV-wiss database
- (2013) K. Laubner et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Efficacy and Safety of Insulin Glargine Compared to Other Interventions in Younger and Older Adults: A Pooled Analysis of Nine Open-Label, Randomized Controlled Trials in Patients with Type 2 Diabetes
- (2013) Naushira Pandya et al. DRUGS & AGING
- Efficacy and Safety of Insulin Degludec in a Flexible Dosing Regimen vs Insulin Glargine in Patients With Type 1 Diabetes (BEGIN: Flex T1): A 26-Week Randomized, Treat-to-Target Trial With a 26-Week Extension
- (2013) Chantal Mathieu et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Observational 6-Month Open-Label Study of Japanese Type 2 Diabetes Patients Switching from NPH Insulin to Insulin Detemir in Basal—Bolus Regimen: 23rd Article of the Japan Diabetes Clinical Data Management Study Group (JDDM23)
- (2013) M Oishi et al. JOURNAL OF INTERNATIONAL MEDICAL RESEARCH
- A randomized trial comparing perinatal outcomes using insulin detemir or neutral protamine Hagedorn in type 1 diabetes
- (2013) Moshe Hod et al. Journal of Maternal-Fetal & Neonatal Medicine
- A randomized trial comparing the rate of hypoglycemia-assessed using continuous glucose monitoring-in 125 preschool children with type 1 diabetes treated with insulin glargine or NPH insulin (the PRESCHOOL study)
- (2013) Thomas Danne et al. PEDIATRIC DIABETES
- Efficacy and safety of insulin degludec three times a week versus insulin glargine once a day in insulin-naive patients with type 2 diabetes: results of two phase 3, 26 week, randomised, open-label, treat-to-target, non-inferiority trials
- (2013) Bernard Zinman et al. Lancet Diabetes & Endocrinology
- Insulin Degludec: A Significant Advancement in Ultralong-Acting Basal Insulin
- (2013) Sanjay Kalra Diabetes Therapy
- Safety and Effectiveness of Insulin Detemir in Different Age-Groups in the A1chieve Study
- (2013) Rachid Malek et al. Diabetes Therapy
- Evolution of Insulin Development: Focus on Key Parameters
- (2012) Joseph M. Tibaldi ADVANCES IN THERAPY
- Better Glycemic Control and Weight Loss With the Novel Long-Acting Basal Insulin LY2605541 Compared With Insulin Glargine in Type 1 Diabetes: A randomized, crossover study
- (2012) J. Rosenstock et al. DIABETES CARE
- A Randomized, Controlled Study of Once-Daily LY2605541, a Novel Long-Acting Basal Insulin, Versus Insulin Glargine in Basal Insulin-Treated Patients With Type 2 Diabetes
- (2012) R. M. Bergenstal et al. DIABETES CARE
- Insulin Degludec Versus Insulin Glargine in Insulin-Naive Patients With Type 2 Diabetes: A 1-year, randomized, treat-to-target trial (BEGIN Once Long)
- (2012) B. Zinman et al. DIABETES CARE
- Maternal Efficacy and Safety Outcomes in a Randomized, Controlled Trial Comparing Insulin Detemir With NPH Insulin in 310 Pregnant Women With Type 1 Diabetes
- (2012) E. R. Mathiesen et al. DIABETES CARE
- The Alteration of Aspart Insulin Pharmacodynamics When Mixed With Detemir Insulin
- (2012) E. Cengiz et al. DIABETES CARE
- Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes
- (2012) T. Heise et al. DIABETES OBESITY & METABOLISM
- Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes
- (2012) T. Heise et al. DIABETES OBESITY & METABOLISM
- A Crossover Comparison of Glycemic Variations in Japanese Patients with Type 1 Diabetes Receiving Insulin Glargine Versus Insulin Detemir Twice Daily Using Continuous Glucose Monitoring (CGM): J COLLECTION (Jikei COmparison of Lantus and LEvemir with Cgm for Thinking Insulin OptimizatioN)
- (2012) Daisuke Tsujino et al. Diabetes Technology & Therapeutics
- Insulin Therapy in Pregnancy
- (2012) Aidan McElduff et al. ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA
- Comparison of Safety and Efficacy of Insulin Glargine and Neutral Protamine Hagedorn Insulin in Older Adults with Type 2 Diabetes Mellitus: Results from a Pooled Analysis
- (2012) Pearl Lee et al. JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
- Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial
- (2012) Alan J Garber et al. LANCET
- Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial
- (2012) Simon Heller et al. LANCET
- Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia
- (2012) NEW ENGLAND JOURNAL OF MEDICINE
- Safety of Insulin Glargine Use in Pregnancy: A Systematic Review and Meta-Analysis
- (2011) Erika Pollex et al. ANNALS OF PHARMACOTHERAPY
- Increase of body weight during the first year of intensive insulin treatment in type 2 diabetes: systematic review and meta-analysis
- (2011) A. E. Pontiroli et al. DIABETES OBESITY & METABOLISM
- A review of modern insulin analogue pharmacokinetic and pharmacodynamic profiles in type 2 diabetes: improvements and limitations
- (2011) M. Evans et al. DIABETES OBESITY & METABOLISM
- Insulin Preparations with Prolonged Effect
- (2011) David R. Owens Diabetes Technology & Therapeutics
- Non-Inferiority of Insulin Glargine Versus Insulin Detemir on Blood Glucose Variability in Type 1 Diabetes Patients: A Multicenter, Randomized, Crossover Study
- (2011) Eric Renard et al. Diabetes Technology & Therapeutics
- Insulin Glargine Use During Pregnancy
- (2011) Kevin Pantalone et al. Endocrine Practice
- Lower HbA1c after 1 year, in children with type 1 diabetes treated with insulin glargine vs. NPH insulin from diagnosis: a retrospective study
- (2011) Jenny Salemyr et al. PEDIATRIC DIABETES
- Two-way crossover comparison of insulin glargine and insulin detemir in basal-bolus therapy using continuous glucose monitoring
- (2011) Satoru Yamada et al. Diabetes Metabolic Syndrome and Obesity-Targets and Therapy
- A 24-Week, Randomized, Treat-to-Target Trial Comparing Initiation of Insulin Glargine Once-Daily With Insulin Detemir Twice-Daily in Patients With Type 2 Diabetes Inadequately Controlled on Oral Glucose-Lowering Drugs
- (2010) S. G. Swinnen et al. DIABETES CARE
- Early Pharmacokinetic and Pharmacodynamic Effects of Mixing Lispro With Glargine Insulin: Results of glucose clamp studies in youth with type 1 diabetes
- (2010) E. Cengiz et al. DIABETES CARE
- Meta-analysis of individual patient data to assess the risk of hypoglycaemia in people with type 2 diabetes using NPH insulin or insulin glargine
- (2010) P. D. Home et al. DIABETES OBESITY & METABOLISM
- Distinct pharmacodynamics of insulin glargine and insulin detemir: Crossover comparison in Type 1 and Type 2 diabetic patients on basal-bolus regimen
- (2010) Tomoko Kato et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Relationship of Insulin Dose, A1c Lowering, and Weight in Type 2 Diabetes: Comparing Insulin Glargine and Insulin Detemir
- (2010) George Dailey et al. Diabetes Technology & Therapeutics
- Comparison of Insulin Detemir and Insulin Glargine on Glycemic Variability in Patients with Type 1 and Type 2 Diabetes
- (2010) A. Tone et al. EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES
- Improved glycaemic control by switching from insulin NPH to insulin glargine: a retrospective observational study
- (2009) Peter Sharplin et al. Cardiovascular Diabetology
- Comparison of insulin detemir and insulin glargine in a basal—bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: A 52-week, multinational, randomized, open-label, parallel-group, Treat-to-Target noninferiority trial
- (2009) Simon Heller et al. CLINICAL THERAPEUTICS
- Comparison of insulin detemir and insulin glargine using a basal-bolus regimen in a randomized, controlled clinical study in patients with type 2 diabetes
- (2009) Philip Raskin et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Insulin detemir improves glycemic control and reduces hypoglycemia in children with type 1 diabetes: findings from the Turkish cohort of the PREDICTIVE™ observational study
- (2009) Selim Kurtoglu et al. PEDIATRIC DIABETES
- A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes
- (2008) Priscilla Hollander et al. CLINICAL THERAPEUTICS
- Comparison of Glycemic Variability Associated With Insulin Glargine and Intermediate-Acting Insulin When Used as the Basal Component of Multiple Daily Injections for Adolescents With Type 1 Diabetes
- (2008) N. H. White et al. DIABETES CARE
- Treatment Satisfaction and Quality of Life With Insulin Glargine Plus Insulin Lispro Compared With NPH Insulin Plus Unmodified Human Insulin in Individuals With Type 1 Diabetes
- (2008) S. G. Ashwell et al. DIABETES CARE
- Long-acting insulin analogues vs. NPH human insulin in type 1 diabetes. A meta-analysis
- (2008) M. Monami et al. DIABETES OBESITY & METABOLISM
- Long-acting insulin analogues versus NPH human insulin in type 2 diabetes
- (2008) Matteo Monami et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Reduced Weight Gain with Insulin Detemir Compared to NPH Insulin Is Not Explained by a Reduction in Hypoglycemia
- (2008) Melanie J. Davies et al. Diabetes Technology & Therapeutics
- Safety and efficacy of glargine compared with NPH insulin for the treatment of Type 2 diabetes: a meta-analysis of randomized controlled trials
- (2008) L. A. Bazzano et al. DIABETIC MEDICINE
- Long-term efficacy and safety of insulin detemir compared to Neutral Protamine Hagedorn insulin in patients with Type 1 diabetes using a treat-to-target basal–bolus regimen with insulin aspart at meals: a 2-year, randomized, controlled trial
- (2008) P. C. Bartley et al. DIABETIC MEDICINE
- Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight Type 2 diabetes patients-The PREDICTIVE™ BMI clinical trial1
- (2008) C. Fajardo Montañana et al. DIABETIC MEDICINE
- A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes
- (2008) J. Rosenstock et al. DIABETOLOGIA
- Switching from NPH insulin to once-daily insulin detemir in basal-bolus-treated patients with diabetes mellitus: data from the European cohort of the PREDICTIVE™ study
- (2008) S. Sreenan et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Insulin Glargine Versus Intermediate-Acting Insulin as the Basal Component of Multiple Daily Injection Regimens for Adolescents with Type 1 Diabetes Mellitus
- (2008) H. Peter Chase et al. JOURNAL OF PEDIATRICS
- Lower fasting blood glucose, glucose variability and nocturnal hypoglycaemia with glargine vs NPH basal insulin in subjects with Type 1 diabetes
- (2008) G.B. Bolli et al. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now